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ABSTRACT
De Quervain’s thyroiditis, also known as subacute thyroiditis (SAT), is a self-limiting inflammatory thyroid disease typically occurring a few weeks 
after a respiratory viral infection. A 29-year-old female with no comorbidities presented with persistent fever, neck pain, and swelling of 10 days 
duration. She also had tremors, fatigue, and palpitation. A careful enquiry revealed that she had been diagnosed with coronavirus disease 2019 
(COVID-19) infection 6 weeks ago and had recovered uneventfully with conservative management. Her laboratories showed leukocytosis, elevated 
erythrocyte sedimentation rate, and C-reactive protein. Thyroid function tests (TFTs) yielded low thyroid-stimulating hormone, and high T3 and 
free T4. Ultrasonography neck was suggestive of thyroiditis. Thyroid scintigraphy demonstrated very low technetium uptake which confirmed SAT. 
Her symptoms ameliorated with nonsteroidal anti-inflammatory drug and beta-blockers and her TFTs improved during follow-up. We report this 
as emerging sequelae of COVID-19 infection. A persistent fever and neck pain following recent COVID-19 infection should alert clinician toward the 
possibility of de Quervain’s thyroiditis following severe acute respiratory syndrome coronavirus 2.
Keywords: Coronavirus disease 2019 infection, De Quervain’s thyroiditis, Severe acute respiratory syndrome coronavirus 2, Subacute thyroiditis, 
Tender goiter.
INTRODUCTION
The World Health Organization declared coronavirus disease 2019 
(COVID-19) as a global pandemic in March 2020. It is caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 
which primarily manifests with acute respiratory symptoms. It is well 
known to produce extrapulmonary symptoms, either at the initial 
presentation or as a later complication. De Quervain’s thyroiditis duet 
to post-COVID-19 sequelae is rarely reported.
Hereby, we report a case of subacute (de Quervain’s) thyroiditis 
triggered by recent SARS-CoV-2 infection. To the best of our knowledge, 
eight cases of subacute thyroiditis (SAT) following COVID-19 infection 
have been reported so far in world literature [1-5], none of them is 
from the Indian population. The purpose of presenting this case is to 
alert clinician about this new complication following COVID-19 as well 
as identify the thyrotoxic symptoms which may be missed during the 
current devastating pandemic.
CASE REPORT
Patient consent was taken for publishing purposes. A 29-year-old female 
medical practitioner with no comorbidities presented to the emergency 
room with persistent high-grade fever and worsening swelling of 
10 days duration associated with pain which was radiating from the left 
side to right side of the neck. The pain was exacerbated by swallowing, 
bending, and turning the neck to the side. History of bilateral hand 
tremors, fatigue, and palpitations for 4 days was also elicited.
A detailed enquiry revealed that 6 weeks before the onset of symptoms, 
she had suffered several days of fever, cough, and other flu-like symptoms. 
Reverse transcriptase-polymerase chain reaction by nasopharyngeal 
swab was positive for SARS-CoV-2 during that time. In about a week of 
conservative treatment, she recovered from her symptoms uneventfully.
She denied the history of trauma, radiation, drug intake like 
amiodarone, lithium, or intravenous contrast and no similar illness in 
the past. Physical examination demonstrated tachycardia, fine tremor 
of extremities, and diffuse and tender goiter. There was no cervical 
lymphadenopathy, eye signs, thrill, or bruit over the thyroid gland. 
Oropharyngeal and general systems examination were normal.
Thyroid function tests (TFTs) showed a very low thyroid-stimulating 
hormone (TSH) (0.007 microU/L) and high T3 (5.05 ng/ml) and free T4 
(7.77 ng/dl) which confirmed hyperthyroidism.
Total leukocyte count (15,100/cu.mm), erythrocyte sediment rate (ESR) 
(70 mm/hr), and C-reactive protein (CRP) (172 mg/L) were elevated.
Microsomal antibodies, thyroglobulin antibodies, and TSH receptor 
antibodies were negative.
Ultrasound (USG) neck demonstrated enlarged heterogeneously 
hypoechoic left lobe of thyroid and isthmus with normal vascularity, 
and bulky right lobe of thyroid with few ill-defined hypoechoic areas 
which suggestive of thyroiditis.
Technetium pertechnetate thyroid scan exhibits no significant uptake 
of the radiotracer (Fig. 1) which confirmed SAT.
The diagnosis of SAT was suspected by her clinical presentation and recent 
COVID-19 infection and it was corroborated with her laboratory findings 
and the absent technetium pertechnetate uptake on a thyroid scan.
She was started on oral indomethacin 25 mg and propanol 40 mg thrice 
daily. Her symptoms subsided and she was discharged after 3 days of 
hospitalization. On 3-week follow-up, she attained remission from her 
symptoms with improvement in TFT (TSH – 0.01 microU/L, free T3 – 
1.1 ng/ml, and FT4 – 1.1 ng/dl).
DISCUSSION
SAT is the most common cause of painful thyroid disease, which 
resulting from the release of preformed thyroid hormones after 
2–8 weeks of viremia in genetically predisposed individuals and has a 
strong association with HLA B35 in many generic groups [6,7].
Case Report
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Fig. 1: Tc99 thyroid scan shows no uptake of the radiotracer
Table 1: List of SAT cases following COVID-19 infection reported in the literature to date
References Current case [1] [2] [2] [2] [2] [3] [4] [5]
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TFT: Thyroid function test, SAT: Subacute thyroiditis, COVID-19: Coronavirus disease 2019, TSH: Thyroid-stimulating hormone, NSAID: Nonsteroidal anti-inflammatory drug
It was first defined by Friz De Quervain in 1904. He distinguished 
this disease pathologically from other forms of thyroiditis. De 
Quervain thyroiditis is also called subacute granulomatous thyroiditis, 
subacute non-suppurative thyroiditis, giant cell thyroiditis, pseudo-
granulomatous thyroiditis, pseudo-tuberculous thyroiditis, or struma 
granulomatosa [7].
The incidence is 12.1 cases per 100,000/year affecting younger and 
middle adulthood age groups with female preponderance. Disease 
frequency decreases with increasing age [8,9]. Viruses such as 
mumps, measles, adenovirus, Epstein-Barr virus, Coxsackie virus, 
influenza, Echovirus, and Enterovirus are commonly associated virus 
causing SAT [9].
However, the incidence of novel COVID-19-induced SAT appears to be 
reporting more during the current pandemic situation. The reported 
case of SAT following COVID-19 infection is enumerated in Table 1.
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Relationship between thyroid and COVID-19 infection
Due to the increased expression of angiotensin-converting enzyme 2 
and transmembrane protease serine 2 levels in the thyroid gland than 
in the lungs, these act as the key routes for virus entry into host cells in 
susceptible patients. Abnormal immunological response and cytokine 
storm due to COVID-19 may also provoke thyroiditis [10].
The natural history of SAT involves four phases, starting with a 
hyperthyroid phase and then followed by a transient asymptomatic 
euthyroid phase, a hypothyroid phase, and a final phase euthyroid 
phase on recovery. Each phase lasts for approximately 4–6 months [11].
The disease classically presents as anterior lower neck pain which 
radiates to upper neck, throat, jaw, or ears and exacerbated by moving 
the head, swallowing, or coughing. Associated flu-like symptoms 
such as fever, malaise, fatigue, and myalgia may be present. Diffuse 
tender thyromegaly with clinical features of hyperthyroidism such as 
tachycardia, tremor, weight loss, palpitation, and anxiety during the 
initial stage is common at presentation [12].
Diagnosis is mainly based on classical clinical history and physical and 
laboratory findings. TFTs should be done initially in all patients with 
suspected SAT followed by ESR and CRP level. Serum anti-thyroid 
peroxidase, anti-thyroglobulin antibodies, and TSH receptor antibodies 
are usually absent or present at low titer. Serum thyroglobulin levels 
may be elevated due to follicular destruction [12].
Radioactive uptake or technetium (99mTc) pertechnetate thyroid scan 
during the hyperthyroid phase helps to confirm the diagnosis. It is due 
to destruction of thyroid follicles with iodine trap defect. USG thyroid 
may help to assess the size, nature, echogenicity, and vascularity of the 
thyroid gland[12].
Characteristics features of Graves’ disease such as exophthalmos, 
pretibial myxedema, thrill, or bruit over thyroid gland are absent. A low 
radioactive iodine uptake study, high ESR, and/or high CRP may help to 
differentiate hyperthyroidism due to SAT from Grave’s disease, which 
has high iodine uptake with normal ESR and CRP. Decreased vascular 
flow patterns in color Doppler USG during the hyperthyroid phase of 
SAT also aid to distinguish it from Graves’ disease, which has increased 
flow [12]. USG-guided fine-needle aspiration cytology is rarely needed 
in doubtful cases with unilateral thyroid involvement, which helps to 
distinguish thyroid abscess, hemorrhage, or thyroid lymphoma from 
SAT [12].
Septic workup is usually needed in patients with fever, and a thorough 
cardiology evaluation may be warranted if tachycardia is present.
Treatment should aim at alleviating anterior neck pain and ameliorating 
thyrotoxic symptoms. Mild-to-moderate pain is usually managed with 
nonsteroidal anti-inflammatory drugs and salicylates. Severe pain can 
be managed with steroids, which provides a dramatic response within 
24–48 h. Hyperthyroid symptoms are best treated with beta-blockers 
such as propanol or atenolol till the free T4 level returns to normal [13].
Hypothyroid phase lasts for shorter periods, and with milder symptoms, 
and hence, treatment is not often required. However, patients with 
moderate-to-severe symptoms can be managed with thyroxine till the 
TSH level returns to normal. In a rare patient with recurrent relapse and 
distressing local symptoms despite sufficient treatment, thyroidectomy 
may be indicated [13].
Regular TFT monitoring should be done every 2–8 weeks to understand 
the natural history of the disease and yearly thereon [13]. Even 
though we could not directly isolate the COVID-19 virus in thyroid 
tissue, current epidemiological and serological reports of our patient 
substantiate viral infection 4 weeks before the onset of SAT.
CONCLUSION
The clinician should have a strong suspicion of SAT in any patient 
presenting with persistent neck pain and odynophagia despite the 
remission of COVID-19 symptoms. Such individuals should be screened 
by TFTs, ESR, CRP, and thyroid imaging (USG or scintigraphy). Early 
identification and anti-inflammatory treatment often result in good 
outcomes.
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